Degradable PLGA scaffolds with basic fibroblast growth factor: Experimental studies in myocardial revascularization

Texas Heart Institute Journal

Volumn 36, Issue 2, 2009, Pages 89-97

  Wang, Ying ^a   Liu, Xiao Cheng ^a,c   Zhao, Jian ^a   Kong, Xiang Rong ^a   Shi, Rong Fang ^a   Zhao, Xiao Bin ^a   Song, Cun Xian ^b   Liu, Tian Jun ^b   Lu, Feng ^b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

^c TEDA INTERNATIONAL CARDIOVASCULAR HOSPITAL   (China)

Author keywords

Angiogenesis inducing agents administration dosage; Disease models, animal; Drug delivery systems methods; Fibroblast growth factors administration dosage; Glycolates; Implants, experimental; Lactic acid; Myocardial infarction; Myocardial ischemia; Neovascularization, physiologic; Polyglycolic acid; Swine; Tissue engineering methods

Indexed keywords

FIBROBLAST GROWTH FACTOR; GLYCOLIC ACID; KI 67 ANTIGEN; POLY(D,L LACTIC COGLYCOLIC ACID); UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABLE IMPLANT; CELL PROLIFERATION; COMPUTER PROGRAM; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; EXPERIMENTAL PIG; HEART DEATH; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MEDICAL INSTRUMENTATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL PROLIFERATION; CORONARY CIRCULATION; CORONARY STENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG IMPLANTS; ECHOCARDIOGRAPHY; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; LACTIC ACID; MYOCARDIAL CONTRACTION; MYOCARDIAL REVASCULARIZATION; NEOVASCULARIZATION, PHYSIOLOGIC; POLYGLYCOLIC ACID; SWINE; SWINE, MINIATURE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR FUNCTION, LEFT;

EID: 65949083997     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis - how many patients might be eligible? Am J Cardiol 1999;84(5):598-600, A8.
2. Henry TD. Therapeutic angiogenesis. BMJ 1999;318(7197):1536-1539
3. Syed IS, Sanborn TA, Rosengart TK. Therapeutic angiogenesis: a biologic bypass. Cardiology 2004;101(1-3):131-143
4. Poole TJ, Finkelstein EB, Cox CM. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn 2001;220(1):1-17.
5. Cox CM, Poole TJ. Angioblast differentiation is influenced by the local environment: FGF-2 induces angioblasts and patterns vessel formation in the quail embryo. Dev Dyn 2000;218(2):371-382
6. Parsons-Wingerter P, Elliott KE, Clark JI, Farr AG. Fibroblast growth factor-2 selectively stimulates angiogenesis of small vessels in arterial tree. Arterioscler Thromb Vasc Biol 2000;20(5):1250-1256
7. Kardami E, Detillieux K, Ma X, Jiang Z, Santiago JJ, Jimenez SK, Cattini PA. Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 2007;12(3-4):267-277
8. Jiang ZS, Padua RR, Ju H, Doble BW, Jin Y, Hao J, et al. Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 2002;282(3):H1071-80.
9. Karsan A, Yee E, Poirier GG, Zhou P, Craig R, Harlan JM. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol 1997;151(6):1775-1784
10. Whalen GF, Shing Y, Folkman J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1989;1(2):157-164
11. Laham RJ, Post M, Rezaee M, Donnell-Fink L, Wykrzykowska JJ, Lee SU, et al. Transendocardial and transepicardial intramyocardial fibroblast growth factor-2 administration: myocardial and tissue distribution. Drug Metab Dispos 2005;33(8):1101-1107
12. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998;65(6):1540-1544
13. Yamamoto M, Ikada Y, Tabata Y. Controlled release of growth factors based on biodegradation of gelatin hydrogel. J Biomater Sci Polym Ed 2001;12(1):77-88.
14. Nillesen ST, Geutjes PJ, Wismans R, Schalkwijk J, Daamen WF, van Kuppevelt TH. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 2007;28(6):1123-1131
15. Teng CJ, Luo J, Chiu RC, Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. J Thorac Cardiovasc Surg 2006;132(3):628-632
16. Thompson JA, Anderson KD, DiPietro JM, Zwiebel JA, Zametta M, Anderson WF, Maciag T. Site-directed neovessel formation in vivo. Science 1988;241(4871):1349-1352
17. Miyoshi M, Kawazoe T, Igawa HH, Tabata Y, Ikada Y, Suzuki S. Effects of bFGF incorporated into a gelatin sheet on wound healing. J Biomater Sci Polym Ed 2005;16(7):893-907.
18. Fujita M, Ishihara M, Morimoto Y, Simizu M, Saito Y, Yura H, et al. Eff icacy of photocrosslinkable chitosan hydrogel containing f ibroblast growth factor-2 in a rabbit model of chronic myocardial infarction. J Surg Res 2005;126(1):27-33.
19. Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, Sellke FW. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002;124(1):28-34.
20. Elcin AE, Elcin YM. Localized angiogenesis induced by human vascular endothelial growth factor-activated PLGA sponge. Tissue Eng 2006;12(4):959-968
21. Schindler A, Jeffcoat R, Kimmel G, Pitt C, Wall M, Zweidinger R. Biodegradable polymers for sustained drug delivery. Contemp Top Polym Sci 1977;2:251-287
22. Wei G, Jin Q, Giannobile WV, Ma PX. Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J Control Release 2006;112(1):103-110
23. Grayson AC, Voskerician G, Lynn A, Anderson JM, Cima MJ, Langer R. Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip. J Biomater Sci Polym Ed 2004;15(10):1281-1304
24. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci U S A 1993;90(4):1513-1517
25. Rajanayagam MA, Shou M, Thirumurti V, Lazarous DF, Quyyumi AA, Goncalves L, et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J Am Coll Cardiol 2000;35(2):519-526
26. Fearon WF, Ikeno F, Bailey LR, Hiatt BL, Herity NA, Carter AJ, et al. Evaluation of high-pressure retrograde coronary venous delivery of FGF-2 protein. Catheter Cardiovasc Interv 2004;61(3):422-428
27. von Degenfeld G, Raake P, Kupatt C, Lebherz C, Hinkel R, Gildehaus FJ, et al. Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood f low and function in pigs with chronic myocardial ischemia. J Am Coll Cardiol 2003;42(6):1120-1128
28. Laham RJ, Rezaee M, Post M, Xu X, Sellke FW. Intrapericardial administration of basic f ibroblast growth factor: myocardial and tissue distribution and comparison with intracoronary and intravenous administration. Catheter Cardiovasc Interv 2003;58(3):375-381
29. Laham RJ, Rezaee M, Post M, Novicki D, Sellke FW, Pearlman JD, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 2000;292(2):795-802.
30. Uchida Y, Yanagisawa-Miwa A, Nakamura F, Yamada K, Tomaru T, Kimura K, Morita T. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J 1995;130(6):1182-1188
31. Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, Unger EF. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 1997;36(1):78-85.
32. Zhao J, Wang Y, Wang GL, Che H, Kong XR, Liu XC. Experimental studies of intramyocardial injecting bone marrow mesenchymal stem cells combined with fibrin sealant in cells transplantation [in Chinese]. Chin J Cardiovasc Rehabil J Med 2007;16(4):321-324
33. Zittermann SI, Issekutz AC. Endothelial growth factors VEGF and bFGF differentially enhance monocyte and neutrophil recruitment to inflammation. J Leukoc Biol 2006;80(2):247-257
34. Anghelina M, Krishnan P, Moldovan L, Moldovan NI. Monocytes/macrophages cooperate with progenitor cells during neovascularization and tissue repair: conversion of cell columns into fibrovascular bundles. Am J Pathol 2006;168(2):529-541
35. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic f ibroblast growth factor, mitogens for vascular cells and f ibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A 1994;91(8):2890-2894
36. Martin TA, Harding KG, Jiang WG. Regulation of angiogenesis and endothelial cell motility by matrix-bound fibroblasts. Angiogenesis 1999;3(1):69-76.
37. Zhou X, Deng Y, Xie L. A study on the mechanism of bFGF promoting endothelial cells to adhere to polyurethane material [in Chinese]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2002;19(3):386-388
38. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, Klagsbrun M. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A 1987;84(8):2292-2296
39. Pintucci G, Moscatelli D, Saponara F, Biernacki PR, Baumann FG, Bizekis C, et al. Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. FASEB J 2002;16(6):598-600.
40. Muraoka N, Shum L, Fukumoto S, Nomura T, Ohishi M, Nonaka K. Transforming growth factor-beta3 promotes mesenchymal cell proliferation and angiogenesis mediated by the enhancement of cyclin D1, Flk-1, and CD31 gene expression during CL/Fr mouse lip fusion. Birth Defects Res A Clin Mol Teratol 2005;73(12):956-965
41. Mountain DJ, Singh M, Menon B, Singh K. Interleukin-1 beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKCalpha/ beta1 and MAPKs. Am J Physiol Cell Physiol 2007;292(2):C867-75.
42. Yamamoto N, Kohmoto T, Roethy W, Gu A, DeRosa C, Rabbani LE, et al. Histologic evidence that basic fibroblast growth factor enhances the angiogenic effects of transmyocardial laser revascularization. Basic Res Cardiol 2000;95(1):55-63.
43. Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, et al. Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur J Cardiothorac Surg 2003;24(1):105-112
44. Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato L, Smith ML, et al. Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study. J Thorac Cardiovasc Surg 2004;127(1):34-43.
45. Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Caputo RP, et al. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp Ther 1997;282(1):385-390
46. Baffour R, Garb JL, Kaufman J, Berman J, Rhee SW, Norris MA, et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J Surg Res 2000;93(2):219-229
47. Malekan R, Reynolds C, Narula N, Kelley ST, Suzuki Y, Bridges CR. Angiogenesis in transmyocardial laser revascularization. A nonspecific response to injury. Circulation 1998;98(19 Suppl):II62-5.
48. Chu VF, Giaid A, Kuang JQ, McGinn AN, Li CM, Pelletier MP, Chiu RC. Thoracic Surgery Directors Association Award. Angiogenesis in transmyocardial revascularization: comparison of laser versus mechanical punctures. Ann Thorac Surg 1999;68(2):301-308
49. Lu H, Xu X, Zhang M, Cao R, Brakenhielm E, Li C, et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc Natl Acad Sci U S A 2007;104(29):12140-12145